Esbriet

August 7, 2018August 14, 2018

Ofev, Esbriet Combo Seen to Be Safe for IPF Patients in Phase 4 Trial

Esbriet, News

Adding Ofev (nintedanib) to Esbriet (pirfenidone) for idiopathic pulmonary fibrosis (IPF) is tolerated by most patients and has a similar safety profile as taking each medication alone, a Phase ... Read more

June 4, 2018June 4, 2018

France Foundation-Genentech Initiative to Improve IPF Diagnosis, Treatment at Local Level

Esbriet, News

Supported by an educational research grant from Genentech, the France Foundation is launching a mentoring and relationship-building program for community healthcare providers to improve how patients with idiopathic pulmonary fibrosis ... Read more

June 1, 2018June 1, 2018

New Lung-on-a-chip Technology Captures Fibrosis Progression and May Speed Treatment Discovery, Study Reports

Esbriet, News

A new lung-on-a-chip technology models the mechanical changes that occur in the lungs during idiopathic pulmonary fibrosis, possibly allowing for a faster and less expensive screening of potential new ... Read more

May 29, 2018May 29, 2018

#ATS2018 – Esbriet Lowers Risk of Seasonal IPF Flares Leading to Hospitalizations, Phase 3 Data Show

Esbriet, News

Seasonal flares of disease activity that can lead to idiopathic pulmonary fibrosis (IPF) patients being hospitalized, especially in the winter months, appear to be effectively countered by treatment with Esbriet (pirfenidone) compared ... Read more

May 14, 2018May 14, 2018

Esbriet and Ofev Use Prior to Lung Transplant Seen as Safe for IPF Patients in Study

Esbriet, News

Treatment with Esbriet (pirfenidone, Genentech) or Ofev (nintedanib, Boehringer Ingelheim), or with steroids was found to be safe for idiopathic pulmonary fibrosis (IPF) patients needing a bilateral lung transplant (BLTx), a study reports. ... Read more

May 4, 2018May 4, 2018

Combo Therapy Seen to Enhance Anti-Fibrotic Activity in Lung Cells from IPF Patients in Early Study

Esbriet, News

A combined treatment, pirfenidone and rapamycin, worked to prevent fibrosis in lung fibroblasts from patients with idiopathic pulmonary fibrosis, new research showed, suggesting a possibly more effective way of treating IPF. ... Read more

March 5, 2018March 5, 2018

Boehringer Ingelheim Launches ‘Why Wait in IPF?’ Campaign, Raising Awareness of Early Diagnosis

Esbriet, News

On last week’s Rare Disease Day, held Feb. 28, Boehringer Ingelheim launched a new campaign titled “Why Wait in IPF?” to raise awareness about the importance of early diagnosis of ... Read more

February 14, 2018February 14, 2018

Advocacy Groups Oppose NICE Opinion Limiting Esbriet to Select IPF Patients in UK

Esbriet, News

patientMpower, a U.K. digitial healthcare and advocacy company, joined others in voicing disappointment with the recent decision of a British advisory board to restrict the use of Esbriet (pirfenidone) to ... Read more

December 20, 2017December 20, 2017

Lung Cancer in IPF Patients Best Treated on ‘Do No Harm’ Basis, Commentary Argues

Esbriet, News

The management of patients with idiopathic pulmonary fibrosis (IPF) and lung cancer should follow the premise “first, do no harm,” researchers argue in the journal The Lancet Respiratory Medicine. ... Read more

November 20, 2017November 20, 2017

Many IPF Patients in Europe Not Given Approved Treatments, Survey Finds

Esbriet, News

Despite the availability of approved antifibrotic treatments for idiopathic pulmonary fibrosis (IPF), many patients in Europe do not receive them, partly due to a lack of awareness by physicians ... Read more

Pin It on Pinterest